Breaking News Instant updates and real-time market news.

WFC

Wells Fargo

, ATHN

athenahealth

$142.67

3.05 (2.18%)

09:35
07/17/17
07/17
09:35
07/17/17
09:35

Dimissal of Wells Fargo insider trading case upheld by SEC, Reuters reports

The dismissal of an administrative case against former Wells Fargo (WFC) trader Joseph Ruggieri, who was accused of trading on tips supplied by a Wells Fargo analyst, has been affirmed by the SEC, Reuters reported this weekend. The SEC alleged that Ruggieri, a healthcare stock trader at Wells Fargo in New York, in 2010 and 2011 traded on tips about six ratings changes made by analyst Gregory Bolan for companies that included Athenahealth (ATHN) and Bruker (BRKR). In last week's ruling, the two SEC commissioners deciding the case deadlocked on a different issue, whether Ruggieri had placed his trades while aware of non-public information. Reference Link

WFC

Wells Fargo

ATHN

athenahealth

$142.67

3.05 (2.18%)

BRKR

Bruker

$28.99

0.15 (0.52%)

  • 21

    Jul

  • 13

    Oct

  • 15

    Jan

WFC Wells Fargo

06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
05/25/17
BERN
05/25/17
NO CHANGE
BERN
Wells Fargo valuation can increase over time, says Bernstein
Bernstein analyst John McDonald says that Wells Fargo's "underlying business remains attractive," citing its "industry leading deposit base,diverse portfolio of fee businesses, large branch network" that could be optimized, and its $300B at the Fed that could be deployed as interest rates increase. The analyst says that the company is looking to cut $4B in costs and should benefit from higher rates. He thinks that its valuation can "rise over time."
05/12/17
BARD
05/12/17
NO CHANGE
Target $58
BARD
Outperform
Wells Fargo slowly turning the corner, says Baird
Baird analyst David George noted Wells Fargo updated its 2017 guidance at its analyst day and reset expectations. He believes the estimates are conservative and continues to like the longer-term risk/reward for Wells Fargo shares. Coupled with its discounted valuation, the downside should be limited, added George, who reiterated his Outperform rating and $58 price target on Wells Fargo.
04/25/17
04/25/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Best Buy (BBY) upgraded to Buy from Neutral at BofA/Merrill with analyst Denise Chai citing stronger than expected product cycles in TVs, phones, and time smart home technology, strong online growth, increased focus on high margin services like subscription warranties and in-home services, and new cost savings opportunities. 2. JPMorgan (JPM) and American Express (AXP) were upgraded to Buy from Neutral at Guggenheim while Wells Fargo (WFC) was upgraded to Neutral from Sell. 3. Crane (CR) upgraded to Outperform from Market Perform at William Blair with analyst Nicholas Heymann citing the company's first quarter results. 4. NCI Building (NCS) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall saying he is more confident in the outlook of the company's end markets and the growth potential of its insulated metal panels business. The analyst believes that worries about the impact of steel price fluctuations on the company's margins are overdone, as he says that hedging can reduce the impact of such fluctuations. 5. Terex (TEX) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying the stock looks undervalued based on the company's 2020 targets. Following Terex's Q1 upside and raised 2017 outlook, the analyst upped her price target for the shares to $47 from $30. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ATHN athenahealth
$142.67

3.05 (2.18%)

06/13/17
CANT
06/13/17
DOWNGRADE
CANT
Neutral
athenahealth downgraded to Neutral from Overweight at Cantor
06/15/17
SBSH
06/15/17
NO CHANGE
Target $163
SBSH
Buy
Citi on Apple buying athenahealth? 'Never say never'
After CNBC reported that Apple (AAPL) is working on making the iPhone into a centralized management of patient health data, Citi analyst Garen Sarafian says athenahealth (ATHN) is a "well-suited candidate" to help. In a research note titled "Apple For athenahealth? Never Say Never," the analyst argues that athenahealth would accelerate Apple's efforts for interoperability. He believes Apple "would be one of few homes" that CEO Jonathan Bush would consider. Sarafian has a Buy rating on athenahealth with a $163 price target. The digital provider of medical records is down 42c to $142.34 in midday trading.
07/17/17
RHCO
07/17/17
NO CHANGE
RHCO
athenahealth could be taken private for more than $150 per share, says SunTrust
After athenahealth's CFO resigned, SunTrust analyst Sandy Draper believes that the company could fetch more than $150 per share in a leveraged buyout. The analyst thinks that under the new CFO, the company could generate "a greater amount of operating leverage and potentially be more receptive to activist interests." He keeps a $150 price target and a Buy rating on the shares.
06/13/17
CANT
06/13/17
DOWNGRADE
Target $140
CANT
Neutral
athenahealth downgraded to Neutral on valuation at Cantor
Cantor Fitzgerald analyst Steven Halper downgraded athenahealth to Neutral from Overweight with the shares at his unchanged price target of $140. The stock now reflects the company's long-term growth potential, Halper tells investors in a research note. He finds it difficult to predict the ultimate outcome of Elliott Associates' 9.2% stake.
BRKR Bruker
$28.99

0.15 (0.52%)

04/25/17
CANT
04/25/17
NO CHANGE
Target $190
CANT
Overweight
Waters price target raised to $190 from $170 at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier raised his price target for Waters (WAT) to $190 citing the company's "strong" Q1 results. Consensus estimates continue under-appreciate the strength in Biopharma, the analyst tells investors in a post-earnings research note. He keeps an Overweight rating on Waters. Brokmeier views the company's earnings report as mixed for peers Bruker (BRKR) and PerkinElmer (PKI).
04/27/17
CLVD
04/27/17
UPGRADE
CLVD
Buy
Bruker upgraded to Buy from Neutral at Cleveland Research
Cleveland Research upgraded Bruker to Buy with a $28 price target following checks that have turned more positive in Europe against relatively easy double-digit comps from 2016 and expects it to be a source of organic growth this year.
06/13/17
MSCO
06/13/17
NO CHANGE
Target $27
MSCO
Equal Weight
Bruker guidance for 2017 will go higher, says Morgan Stanley
Morgan Stanley analyst Steve Beuchaw review of end market trends indicates Bruker has experienced a recent improvement in European chemical/industrial and in China manufacturing. As a result, the analyst raised 2017 earnings by 7% to $1.22, versus consensus of $1.09. Beuchaw believes shares can go higher near-term as consensus moves higher but said comps are tough in 2018 and maintains an Equal Weight rating and a $27 price target on Bruker shares.
03/27/17
JANY
03/27/17
DOWNGRADE
JANY
Neutral
Bruker downgraded to Neutral from Buy at Janney Capital

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.